The "before and after" you see in marketing is almost always the top decile of responders on top doses. Real-world data tells a different story: a real-world cohort of 2,405 patients on older GLP-1s at glycemic-control doses lost only 2.2% of body weight at 72 weeks — far below the 15% from STEP trials of high-dose semaglutide. The gap matters because expectations set during the first weeks shape whether someone stays on the drug long enough to see the real curve.
Direct answer: Trial-level data shows a predictable arc on high-dose GLP-1s: 2–5% in month 1, 8–11% by month 6, 14–22% by month 12, plateau by month 18. Tirzepatide produces about 5–7 percentage points more weight loss than semaglutide at top doses. Real-world results land lower because of dose adherence, lower-dose prescribing, and missed doses. Body composition changes (waist, fat mass, A1C, BP, sleep) often outpace what the scale shows in months 7–12.
The Average Trial Curve
Based on STEP, SURMOUNT, and head-to-head data, the typical patient on a high-dose GLP-1 for obesity follows this curve:
| Time on GLP-1 | Semaglutide 2.4 mg | Tirzepatide 15 mg | Approx lb on 200-lb starting weight |
|---|---|---|---|
| Weeks 1–2 | 0.5–1% (1–2 lb) | 0.5–1% (1–2 lb) | Mostly water |
| Month 1 | 2–5% | 2–5% | 4–10 lb |
| Month 2 | 4–7% | 5–8% | 8–16 lb |
| Month 3 | 5–8% (5.9% in pooled real-world data) | 7–10% | 10–20 lb |
| Months 4–6 | 10–14% (10.9% real-world) | 12–17% | 20–34 lb |
| Months 7–9 | 12–14% | 15–18% | 24–36 lb |
| Months 10–12 | 14–15% (15% STEP target) | 18–20% | 28–40 lb |
| Months 13–18 | 15–17% | 20–22.5% (21% SURMOUNT) | 30–45 lb |
Retatrutide trials (not yet approved) point higher: ~24% at 48 weeks at 12 mg.
What Real-World Numbers Look Like
A 2,405-patient cohort study of patients on liraglutide (52%), dulaglutide (40%), and other older GLP-1s — at glycemic-control doses, not high obesity doses:
| Time point | Mean weight loss | % achieving ≥5% loss | % achieving ≥10% loss |
|---|---|---|---|
| 8 weeks | 1.1% | 11.2% | n/a |
| 72 weeks | 2.2% (~6 lb on 238-lb baseline) | 33.3% | 10.5% |
Why so much lower than trials?
- These patients were on lower-dose, older drugs for diabetes, not high-dose weight-loss formulations
- Real-world dose escalation is slower and often stops short of the target
- Adherence drops over time
- Half don't take the medication consistently
The headline lesson: trial numbers are the best case at top doses with full adherence. Real-world numbers are 30–60% of the trial result.
Month By Month: What Actually Happens
Month 1: Adjustment
Most of the early loss is water as glycogen drops. The medication is in titration; the dose has not reached therapeutic levels for weight loss.
- 2–5 lb loss
- Food noise quiets noticeably — often the biggest "wow" moment
- Mild nausea, especially the first 3–4 days after each dose
- Energy can dip if calories drop too fast
Don't compare your month 1 to anyone else's; the dose has not been titrated up yet.
Months 2–3: Momentum
This is when most people see meaningful changes. Dose has reached the first real therapeutic level.
- 1–2 lb per week typical
- Clothes start fitting differently before the scale moves dramatically
- Cravings continue dropping
- Small plateau around week 8 is common — usually resolves with the next dose increase
- Real-world cohort data: 5.9% mean loss at 3 months
Months 4–6: The Visible Phase
The "before vs now" photos start to look meaningfully different.
- 4–8 lb/month
- Real-world cohort: 10.9% at 6 months
- Body composition shifts — fat mass drops, lean mass mostly preserved (especially if eating ≥1.2 g/kg protein and resistance training)
- Major plateau common around months 4–5 — usually short
- Some patients reach maintenance dose during this phase
Months 7–12: The Long Tail
The curve flattens. Many people get frustrated here.
- 0.5–1 lb/week is normal
- Trial outcome at 12 months: ~15% on semaglutide, ~21% on tirzepatide
- Smaller scale changes, bigger body composition changes
- Resistance training matters most here for preserving lean mass
- Plateaus of 4–6 weeks are common and usually break on their own
Months 13–18: Flattening Out
Most people on a stable dose are within a few pounds of their maximum response.
- Semaglutide 2.4 mg: 15–17%
- Tirzepatide 15 mg: 20–22.5%
- Retatrutide 12 mg (trials): ~24%
After this point, more weight loss usually requires a dose increase, a switch to a more potent agent, or structured training.
What Changes Besides the Scale
The before-and-after photo captures only one dimension. The fuller list of measurable changes after 6–12 months:
| Measure | Typical change |
|---|---|
| Waist circumference | -4 to -8 inches |
| Body fat % | -5 to -10 percentage points |
| A1C (if diabetic) | -1 to -2 percentage points |
| Blood pressure | -10 to -15 mmHg systolic |
| Triglycerides | -20 to -30% |
| LDL cholesterol | -5 to -10% |
| HDL cholesterol | +5 to +10% |
| Resting heart rate | -3 to -5 bpm |
| Sleep apnea events (AHI) | Often 25+/hour reduction |
| Knee/hip pain | Often reduced |
| ALT/AST (liver) | Often normalized |
Individual Variation: Why Some Lose Faster
Trials show wide spreads around the mean. At 12 months on semaglutide 2.4 mg, the 90th percentile loses ~25%; the 10th percentile loses ~5%. Drivers of the spread:
- Age: younger (<45) responds faster
- Starting BMI: higher BMI tends to lose more absolute weight but similar percent
- Sex: women lose slightly slower on average
- Dose adherence: missing doses or staying on low doses caps response
- Protein intake: higher protein preserves muscle and resting metabolic rate
- Sleep: poor sleep measurably blunts response
- Strength training: preserves lean mass, prevents metabolic adaptation
- Thyroid status: untreated hypothyroidism slows response
- Other meds: sulfonylureas, certain antidepressants can blunt loss
- Genetics: real effect, small magnitude
Realistic Photo Comparisons
Before-and-after photos used in marketing are usually from people in the top decile. A more honest comparison:
- 3 months: Mild change. Face usually slimmer first. Pants fit differently.
- 6 months: Visible difference to people who haven't seen you for a while.
- 12 months: Clearly different person in clothes. Body fat distribution has shifted.
- 18 months: Stable. Skin has had time to adapt.
Real Patient Stories (Composite)
From published patient profiles:
- Pepper Schwartz (not diabetic) lost ~30 lb on Ozempic with improved BP and cholesterol
- Gina Schweppe (overweight + pre-diabetes + hyperthyroidism) lost ~35 lb in 3 months on a GLP-1 with diet and exercise
- Jamel Corona lost ~60 lb on Wegovy with food discipline and regular activity
These are real outcomes, not marketing — but they are the upper end of typical, not the median.
When To Worry
The arc above is the average. Reasons to talk to a prescriber:
- No weight loss after 12 weeks at the therapeutic dose
- Rapid weight loss of >2% per week sustained for more than 4 weeks
- Persistent symptoms that don't resolve between doses
- Unintended weight loss beyond your goal
- Plateau lasting more than 12 weeks — sometimes the answer is a dose increase, switch, or paired strength program
- Significant lean mass loss on DEXA — usually a sign protein and training need work
What People Get Wrong About Before-and-Afters
- "It stopped working after 6 months." It is supposed to slow down. The curve is not linear.
- "My friend lost 30 lb in 3 months on Wegovy — why am I not?" Top-decile responses are not the median.
- "The picture is what counts." Body composition matters more than scale weight.
- "After I stop, the weight will stay off." Most regain 1/3 to 2/3 of the loss within a year of stopping unless transition strategies are in place.
- "Real-world results match the trials." They usually don't, mostly because dose, adherence, and lifestyle differ from trial conditions.
Frequently Asked Questions
How much weight will I lose in the first month on GLP-1? Average is 2–5 lb in month 1. Most of that is glycogen and water; real fat loss accelerates in months 2–3.
What is the typical 6-month result? Trial data: 10–14% of starting body weight. Real-world data: closer to 5–8% depending on the drug, dose, and adherence.
What is the average 1-year weight loss on Wegovy? About 15% in STEP trials. Real-world cohorts show 3–8% at standard doses with imperfect adherence.
Is tirzepatide before-and-after better than semaglutide? On average yes — tirzepatide produces about 5–7 percentage points more weight loss at 72 weeks (~21% vs ~15%).
Why has my weight loss stalled? Plateaus of 4–6 weeks are normal. Sleep, protein, dose level, alcohol, and stress are the usual culprits. Persistent plateaus often resolve with a dose adjustment or change in training.
Will I keep the weight off after stopping? Without structured transition (slow taper, strength training, food rules), about 1/3 to 2/3 of the loss returns within 12 months.
Last reviewed: May 13, 2026
